Please login to the form below

Not currently logged in
Email:
Password:

Strensiq

This page shows the latest Strensiq news and features for those working in and with pharma, biotech and healthcare.

Alexion adds to pipeline rebuild with $855m Wilson buy

Alexion adds to pipeline rebuild with $855m Wilson buy

A $1bn purchase of Enobia in 2011 gave it an enzyme therapy for the ultra-orphan disease hypophosphatasia (HPP) - Strensiq (asfotase alfa) - which made $340m in sales last year but still

Latest news

  • NICE broadens access to Alexion's rare disease drug Strensiq NICE broadens access to Alexion's rare disease drug Strensiq

    NICE broadens access to Alexion's rare disease drug Strensiq. New deal offers NHS England a discount for the drug. ... More babies with the rare and life-threatening disease paediatric-onset hypophosphatasia (HPP) will be able to get access to Alexion's

  • NICE blocks second Alexion rare disease drug in a week NICE blocks second Alexion rare disease drug in a week

    The verdict comes just days after the agency excluded two patient groups in its final determination on rare bone disorder drug Strensiq (asfotase alfa), giving the go-ahead only for perinatal- ... After the Strensiq appraisal concluded Alexion criticised

  • AZ, BMS and Boehringer among UK Prix Galien finalists AZ, BMS and Boehringer among UK Prix Galien finalists

    asfotase alfa. Strensiq. Alexion. paediatric-onset hypophosphatasia (HPP) - bone manifestations. Real World Evidence Award 2016 finalists.

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    These were Kanuma (sebelipase alfa), the first-ever treatment for the rare, inherited disorder lysosomal acid lipase deficiency - and Strensiq (asfotase alfa), the first enzyme replacement therapy for patients with infantile- ... Alkermes. USA. asfotase

  • Alexion's rare bone disorder therapy rejected by NICE Alexion's rare bone disorder therapy rejected by NICE

    Alexion's rare bone disorder therapy rejected by NICE. Draft guidance rules Strensiq does not have a compelling enough evidence base. ... The US decision may signal that Alexion is prepared to be flexible on Strensiq's price in England.

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics